Followers | 240 |
Posts | 12032 |
Boards Moderated | 2 |
Alias Born | 04/05/2009 |
Thursday, June 18, 2015 9:13:12 PM
ELMSFORD, N.Y., June 18, 2015 /PRNewswire/ -- BioScrip, Inc. (NASDAQ: BIOS) (the "Company") today announced that its Board of Directors set the record date for the previously disclosed upcoming rights offering (the "Rights Offering") as of the close of business June 25, 2015 (the "Record Date"). The Company expects the Rights Offering will commence no later than June 30, 2015 and conclude by the end of July 2015. On the commencement date, or as soon as practicable thereafter, the Company will distribute the subscription rights, non-transferable subscription rights certificates and copies of the prospectus to stockholders of record as of 5:00 p.m. New York City time on the Record Date.
As previously announced, stockholders of record will receive, at no charge, their pro rata share of non-transferable subscription rights with respect to the outstanding shares of common stock owned by them on the Record Date, subject to rounding adjustment as contemplated by the terms of the Rights Offering. The subscription rights are for the purchase of units consisting up to an aggregate of (1) 200,000 shares of 8.5%/11.5% Series A convertible preferred stock, (2) 576,000 Class A warrants, each full warrant to purchase one share of the Company's common stock ("Common Stock") at a price of $5.17 per share, and (3) 576,000 Class B warrants, each full warrant to purchase one share of Common Stock at a price of $6.45 per share.
This press release is for informational purposes only. Additional details regarding the Rights Offering are included in the Company's Form S-3 filed with the Securities and Exchange Commission (the "SEC") on March 10, 2015, as amended on May 29, 2015 (File No. 333-202631), and the Company will be filing a final prospectus at the time the Rights Offering is commenced, which will contain final terms. The rights and securities offered for subscription thereunder may not be sold, nor may offers to buy be accepted, prior to the time such registration statement becomes effective. The Rights Offering is being made only pursuant to the prospectus and non-transferable subscription rights certificate, both of which are being distributed to holders of common stock and have been filed with the SEC as part of such registration statement.
The Company continues to evaluate market conditions and financing options that would improve its current liquidity profile and enhance its financial flexibility. This may include, but is not limited to, opportunities to raise additional funds through the issuance of various forms of equity and/or debt securities or other instruments, including additional rights offerings.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these rights offering securities, nor shall there be any sale of these rights offering securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A written prospectus for the Rights Offering, when available, may be obtained by contacting Georgeson Inc., 480 Washington Blvd., 26th Floor, Jersey City, NJ 07310, Tel: (877) 278-4775.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. BioScrip provides its infusion services from over 70 locations across 28 states.
http://www.prnewswire.com/news-releases/bioscrip-inc-announces-record-date-for-rights-offering-300101752.html
"Someone said it takes 30 years to be an instant success" - Gabriel Barbier-Mueller, CEO of Harwood International
Recent BIOS News
- BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate • GlobeNewswire Inc. • 10/04/2023 11:30:00 AM
- Avertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business Combination • GlobeNewswire Inc. • 10/04/2023 11:30:00 AM
- Heart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient Monitoring • GlobeNewswire Inc. • 08/16/2023 12:30:27 PM
- Renown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of Directors • GlobeNewswire Inc. • 07/17/2023 12:00:10 PM
- Avertix’s Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth Orlando • GlobeNewswire Inc. • 06/13/2023 12:30:00 PM
- Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation • GlobeNewswire Inc. • 05/03/2023 12:30:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM